Famotidine in the treatment of functional dyspepsia: A randomized double-blind, placebo-controlled trial

Journal of the Egyptian Public Health Association

Volumn 87, Issue 1-2, 2012, Pages 29-33

  Amini, Mohsen ^a,b   Chehreh, Mohammad Ebrahim Ghamar ^a,b   Khedmat, Hossein ^a,b   Valizadegan, Ghasem ^a   Babaei, Marzieh ^a   Darvishi, Ahmad ^a   Taheri, Saeed ^c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Baqiyatallah Research Center for Gastroenterology and Liver Disease   (Iran)

^c Dr Taheri Medical Research Group   (Iran)

Author keywords

Double blind controlled trial; Famotidine; Functional dyspepsia; Placebo

Indexed keywords

FAMOTIDINE;

CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; HUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; DYSPEPSIA; FAMOTIDINE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84861021462     PISSN: 00132446     EISSN: 2090262X     Source Type: Journal    
DOI: 10.1097/01.EPX.0000410948.64665.66     Document Type: Article

References (12)

1. Klauser AG, Voderholzer WA, Knesewitsch PA, Schindlbeck NE, Muller Lissner SA. What is behind dyspepsia? Dig Dis Sci 1993; 38:147-154. (Pubitemid 23039467)
2. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GNJ. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl 2): II37-II42. (Pubitemid 29434811)
3. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127:1239-1255. (Pubitemid 39345892)
4. Allescher HD, Böckenhoff A, Knapp G,Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36:934-941. (Pubitemid 32681456)
5. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-1479.
6. Kato M,Watanabe M, Konishi S, Kudo M, Konno J, Meguro T, et al. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther 2005; 21:27-31. (Pubitemid 40806577)
7. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005; 21:32-36. (Pubitemid 40806578)
8. Kinoshita Y, Hashimoto T, Kawamura A, Yuki M, Amano K, Sato H, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005; 21:37-41. (Pubitemid 40806579)
9. Otaka M, Jin M, Odashima M, Matsuhashi T,Wada I, Horikawa Y, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005; 21:42-46. (Pubitemid 40806580)
10. Redstone HA, Barrowman N, Van Veldhuyzen Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15:1291-1299. (Pubitemid 32835534)
11. Dammann HG. Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. Hepatogastroenterology 1990; 37 (Suppl 1): 2-5. (Pubitemid 20230813)
12. Finney JS, Kinnersley N, Hughes M, O'Bryan Tear CG, Lothian J. Metaanalysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26:312-320. (Pubitemid 28272513)